# A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

> **NCT00720434** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 35 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** PF-00868554
- **DRUG:** PF-00868554
- **DRUG:** PF-00868554
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00720434
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720434, "A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00720434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*